The Nasdaq Biotech Index surged 8 percent between Friday and Wednesday, which is the best three-day run since President Trump was elected in November, according to the report.
In January, when President Trump openly criticized pharmaceutical companies, saying they are “getting away with murder,” biotech stocks plummeted as fears erupted that his administration would place aggressive restraints on drug prices. However, these fears are dispersing as the executive order reportedly favors the drug industry, according to Bloomberg Politics.
“It just sounds more and more likely that the focus is going to be on removing barriers to entry rather than a direct attack on pricing,” Brian Skorney, an analyst at Robert W. Baird & Co., told Bloomberg Politics. “That’s a pretty industry-friendly scenario if it does end up occurring.”
More articles on supply chain:
Drug manufacturer, distributor shut down for producing unapproved medications
Sanofi CEO on SCOTUS’ biologics ruling: 3 takeaways
Whole Foods acquisition could move Amazon closer to pharmacies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.